Krystal Biotech (NASDAQ:KRYS – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.
Institutional and Insider Ownership
86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Krystal Biotech and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Krystal Biotech | 54.82% | 19.34% | 17.65% |
| Madrigal Pharmaceuticals | -25.32% | -56.65% | -25.53% |
Earnings & Valuation
This table compares Krystal Biotech and Madrigal Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Krystal Biotech | $389.13 million | 25.10 | $204.83 million | $7.98 | 41.35 |
| Madrigal Pharmaceuticals | $958.40 million | 11.08 | -$288.28 million | ($12.89) | -35.67 |
Krystal Biotech has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Krystal Biotech has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Krystal Biotech and Madrigal Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Krystal Biotech | 0 | 2 | 10 | 2 | 3.00 |
| Madrigal Pharmaceuticals | 1 | 2 | 15 | 0 | 2.78 |
Krystal Biotech presently has a consensus target price of $377.20, indicating a potential upside of 14.30%. Madrigal Pharmaceuticals has a consensus target price of $699.20, indicating a potential upside of 52.06%. Given Madrigal Pharmaceuticals’ higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Krystal Biotech.
Summary
Krystal Biotech beats Madrigal Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
